دورية أكاديمية
Human CD79b + neutrophils in the blood are associated with early-stage melanoma.
| العنوان: | Human CD79b + neutrophils in the blood are associated with early-stage melanoma. |
|---|---|
| المؤلفون: | Meyer MA; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Dinh HQ; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States.; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, WI, United States., Alimadadi A; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Araujo DJ; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Chatterjee N; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Gutierrez NA; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Zhu YP; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States.; Department of Pediatrics, School of Medicine, University of California, San Diego, San Diego, CA, United States.; School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton, United Kingdom., Hunter EL; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Liang S; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Seumois G; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Kiosses WB; Microscopy and Histology Core Facility, La Jolla Institute for Immunology, La Jolla, CA, United States., Catz SD; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, United States., Vijayanand P; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States., Ottensmeier C; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States.; School of Cancer Sciences, University of Southampton Faculty of Medicine, Southampton, United Kingdom.; Institute of Translational Medicine, Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom., Hedrick CC; Center for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, United States.; Immunology Center of Georgia, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Oct 31; Vol. 14, pp. 1224045. Date of Electronic Publication: 2023 Oct 31 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Leukemia, Lymphocytic, Chronic, B-Cell* , Melanoma*, Humans ; Neutrophils ; Antigens, CD19 ; B-Lymphocytes |
| مستخلص: | Purpose: Due to their abundance in the blood, low RNA content, and short lifespan, neutrophils have been classically considered to be one homogenous pool. However, recent work has found that mature neutrophils and neutrophil progenitors are composed of unique subsets exhibiting context-dependent functions. In this study, we ask if neutrophil heterogeneity is associated with melanoma incidence and/or disease stage. Experimental Design: Using mass cytometry, we profiled melanoma patient blood for unique cell surface markers among neutrophils. Markers were tested for their predictiveness using flow cytometry data and random forest machine learning. Results: We identified CD79b + neutrophils (CD3 - CD56 - CD19 - Siglec8 - CD203c - CD86 Lo CD66b + CD79b + ) that are normally restricted to the bone marrow in healthy humans but appear in the blood of subjects with early-stage melanoma. Further, we found CD79b + neutrophils present in tumors of subjects with head and neck cancer. AI-mediated machine learning analysis of neutrophils from subjects with melanoma confirmed that CD79b expression among peripheral blood neutrophils is highly important in identifying melanoma incidence. We noted that CD79b + neutrophils possessed a neutrophilic appearance but have transcriptional and surface-marker phenotypes reminiscent of B cells. Compared to remaining blood neutrophils, CD79b + neutrophils are primed for NETosis, express higher levels of antigen presentation-related proteins, and have an increased capacity for phagocytosis. Conclusion: Our work suggests that CD79b + neutrophils are associated with early-stage melanoma. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AR declared a shared affiliation with the authors YZ and CO to the handling editor at the time of review. (Copyright © 2023 Meyer, Dinh, Alimadadi, Araujo, Chatterjee, Gutierrez, Zhu, Hunter, Liang, Seumois, Kiosses, Catz, Vijayanand, Ottensmeier and Hedrick.) |
| References: | PLoS Pathog. 2018 May 21;14(5):e1007073. (PMID: 29782541) Sci Immunol. 2018 Dec 7;3(30):. (PMID: 30530726) J Immunother Cancer. 2019 Feb 20;7(1):50. (PMID: 30786924) Nucleic Acids Res. 2013 May 1;41(10):e108. (PMID: 23558742) Trends Immunol. 2003 Jun;24(6):302-6. (PMID: 12810105) Cancer Cell. 2016 Jul 11;30(1):120-135. (PMID: 27374224) J Leukoc Biol. 1991 Apr;49(4):317-28. (PMID: 1825838) J Leukoc Biol. 2013 Oct;94(4):595-601. (PMID: 23625199) Nat Rev Immunol. 2018 Feb;18(2):134-147. (PMID: 28990587) Cell Struct Funct. 2008;33(1):1-12. (PMID: 18256512) Blood. 2017 Apr 6;129(14):1991-2001. (PMID: 28143882) J Immunother Cancer. 2023 Feb;11(2):. (PMID: 36750254) Immunity. 2019 May 21;50(5):1317-1334.e10. (PMID: 30979687) Front Immunol. 2017 Dec 11;8:1781. (PMID: 29321780) PLoS One. 2013 Dec 05;8(12):e82237. (PMID: 24340008) Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677) Cancer. 2015 Jan 1;121(1):51-9. (PMID: 25155861) J Immunother Cancer. 2020 Sep;8(2):. (PMID: 32912924) J Transl Med. 2022 Oct 15;20(1):469. (PMID: 36243798) Immunity. 2020 Aug 18;53(2):319-334.e6. (PMID: 32814027) Bioinformatics. 2010 Jun 15;26(12):1572-3. (PMID: 20427518) Nat Rev Immunol. 2019 Apr;19(4):255-265. (PMID: 30816340) Blood. 2011 Jan 27;117(4):1196-204. (PMID: 21051556) Immunity. 2015 Jul 21;43(1):132-45. (PMID: 26187412) Curr Treat Options Oncol. 2022 Apr;23(4):562-577. (PMID: 35298769) Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308) Cell. 2015 Jul 2;162(1):184-97. (PMID: 26095251) Nat Commun. 2021 Aug 9;12(1):4791. (PMID: 34373452) Cell Rep. 2015 Feb 3;10(4):562-73. (PMID: 25620698) J Vis Exp. 2019 Jun 19;(148):. (PMID: 31282876) Immunity. 2020 Aug 18;53(2):303-318.e5. (PMID: 32579887) Genome Biol. 2014 Feb 03;15(2):R29. (PMID: 24485249) Cancers (Basel). 2020 Nov 13;12(11):. (PMID: 33202891) Cytometry A. 2013 May;83(5):483-94. (PMID: 23512433) Immunity. 2018 Feb 20;48(2):364-379.e8. (PMID: 29466759) J Leukoc Biol. 2012 Jan;91(1):167-81. (PMID: 21954284) Nat Med. 2020 Jul;26(7):1070-1076. (PMID: 32514174) Immunity. 2020 Jan 14;52(1):183-199.e9. (PMID: 31924475) Cell Rep. 2022 Aug 16;40(7):111171. (PMID: 35977505) Stem Cell Reports. 2017 Feb 14;8(2):346-359. (PMID: 28111277) Cell Rep. 2018 Aug 28;24(9):2329-2341.e8. (PMID: 30157427) Sci Rep. 2022 Nov 19;12(1):19920. (PMID: 36402888) Annu Rev Immunol. 2001;19:595-621. (PMID: 11244048) Blood. 2003 Mar 1;101(5):1950-5. (PMID: 12406913) Cytometry A. 2019 Mar;95(3):268-278. (PMID: 30549398) PLoS Comput Biol. 2016 Sep 23;12(9):e1005112. (PMID: 27662185) Hum Immunol. 2012 Nov;73(11):1087-90. (PMID: 22902398) Front Immunol. 2020 Sep 16;11:1749. (PMID: 33042107) Methods Mol Biol. 2018;1799:275-302. (PMID: 29956159) |
| معلومات مُعتمدة: | U01 CA224766 United States CA NCI NIH HHS; R01 HL088256 United States HL NHLBI NIH HHS; P30 CA168524 United States CA NCI NIH HHS; T32 AR064194 United States AR NIAMS NIH HHS; R35 GM150893 United States GM NIGMS NIH HHS; R01 CA202987 United States CA NCI NIH HHS; R01 HL134236 United States HL NHLBI NIH HHS; S10 OD018499 United States OD NIH HHS; P01 HL152958 United States HL NHLBI NIH HHS; P01 HL136275 United States HL NHLBI NIH HHS |
| فهرسة مساهمة: | Keywords: CD79b; biomarker; mass cytometry; melanoma; neutrophils |
| المشرفين على المادة: | 0 (Antigens, CD19) |
| تواريخ الأحداث: | Date Created: 20231129 Date Completed: 20231201 Latest Revision: 20240615 |
| رمز التحديث: | 20240615 |
| مُعرف محوري في PubMed: | PMC10643866 |
| DOI: | 10.3389/fimmu.2023.1224045 |
| PMID: | 38022639 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1224045 |